Biomarkers in Neuropsychiatry最新文献_第4页

Altered brain dopamine metabolism is a trait marker for bipolar disorder 大脑多巴胺代谢改变是双相情感障碍的特征标志

Biomarkers in Neuropsychiatry Pub Date : 2023-09-30 DOI: 10.1016/j.bionps.2023.100078

Erik Pålsson , Carl Sellgren , Aurimantas Pelanis , Henrik Zetterberg , Kaj Blennow , Mikael Landén

{"title":"Altered brain dopamine metabolism is a trait marker for bipolar disorder","authors":"Erik Pålsson , Carl Sellgren , Aurimantas Pelanis , Henrik Zetterberg , Kaj Blennow , Mikael Landén","doi":"10.1016/j.bionps.2023.100078","DOIUrl":"https://doi.org/10.1016/j.bionps.2023.100078","url":null,"abstract":"<div><p>Pharmacological treatment, imaging, and neurochemistry studies identify altered dopamine signaling in bipolar disorder. Our previous work has shown higher concentration of homovanillic acid (HVA), the end metabolite of dopamine, in cerebrospinal fluid (CSF) from individuals with bipolar disorder compared to healthy controls. Here, we analyzed HVA concentrations from a follow-up visit in 103 adults with bipolar disorder and 57 controls from our first cohort. Further, we analyzed CSF monoamine metabolite concentrations in a second cohort of 152 adults with bipolar disorder and 55 controls. At the follow-up visit for the first cohort, HVA was higher in individuals with bipolar disorder (278 ± 102 nmol/L, p = 0.003) compared with controls (232 ± 83 nmol/L). In the second cohort, individuals with bipolar disorder had higher HVA (272 ± 97 nmol/L, p = 0.001) and lower 3-methoxy-4-hydroxyphenylglycol (MHPG, 40 ± 9 nmol/L, p = 0.002) concentrations than controls (HVA, 231 ± 71 nmol/L and MHPG, 45 ± 9 nmol/L). Baseline and follow-up measures of monoamine metabolites showed medium to high correlation to each other but did not predict course of illness. We failed to replicate the association of HVA concentration and psychotic symptoms but confirmed lower 5-hydroxyindoleacetic acid (5-HIAA) concentration in individuals treated with antidepressants. In conclusion, we confirmed high HVA concentration in CSF in patients with bipolar disorder compared to a control group. Previous work suggest that this is a feature shared with ADHD but distinct from schizophrenia and major depressive disorder. The role of increased HVA concentration in the course of illness in bipolar disorder remains unclear.</p></div>","PeriodicalId":52767,"journal":{"name":"Biomarkers in Neuropsychiatry","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50187069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular biomarkers and cognitive impairment in multiple sclerosis: A review 多发性硬化症的分子生物标志物与认知障碍：综述

Biomarkers in Neuropsychiatry Pub Date : 2023-09-29 DOI: 10.1016/j.bionps.2023.100077

Sara Esmaeili , Ahmed Z. Obeidat , Aram Zabeti

{"title":"Molecular biomarkers and cognitive impairment in multiple sclerosis: A review","authors":"Sara Esmaeili , Ahmed Z. Obeidat , Aram Zabeti","doi":"10.1016/j.bionps.2023.100077","DOIUrl":"https://doi.org/10.1016/j.bionps.2023.100077","url":null,"abstract":"<div><p>Cognitive Impairment (CI) is one of the most common and devastating manifestations in patients with Multiple Sclerosis (MS), which directly impacts the quality of life (QOL) and increases the burden of the disease. Years ago, CI was underrated but recently has gained far more attention from scientists in this field. The baseline pathophysiology and exact brain changes leading to CI are yet to be known. Both inflammatory and neurodegenerative processes could be contributing to CI. As a result, the diagnosis of subtle changes, especially in the early phases of the disease, along with the detection of changes throughout the disease course, is of utmost challenging debate among healthcare providers. Conventional Imaging techniques and usual neuropsychiatric screening tests may not detect early CI, rendering some cases missed. Serum or cerebrospinal fluid biomarkers are promising surrogates to detect the CI in these patients. The field of biomarkers in MS is evolving, and growing evidence indicates its applicability in decision-making. In this review, we focused on serum and CSF biomarkers that correlate with the CI in MS. In the end, we briefly discussed the future path in this regard.</p></div>","PeriodicalId":52767,"journal":{"name":"Biomarkers in Neuropsychiatry","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50187068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of ABO blood types with psychiatric disorders: Potential biomarkers of genetic susceptibility? ABO血型与精神疾病的关系：遗传易感性的潜在生物标志物？

Biomarkers in Neuropsychiatry Pub Date : 2023-09-25 DOI: 10.1016/j.bionps.2023.100076

Ishani Paul, Henry A. Nasrallah

{"title":"Association of ABO blood types with psychiatric disorders: Potential biomarkers of genetic susceptibility?","authors":"Ishani Paul, Henry A. Nasrallah","doi":"10.1016/j.bionps.2023.100076","DOIUrl":"https://doi.org/10.1016/j.bionps.2023.100076","url":null,"abstract":"<div><h3>Background</h3><p>Published reports have suggested associations between ABO blood type and various medical conditions such as duodenal ulcers or stomach carcinomas. Studies have also linked this blood type to preoperative anxiety, indicating a possible psychiatric connection. This prompted us to review the literature for possible associations between blood types and one or more psychiatric disorders in controlled studies.</p></div><div><h3>Methods</h3><p>Using search engines including PubMed and Google Scholar, we used the key words “ABO blood types”, “depression”, “anxiety”, “schizophrenia”, “bipolar disorder”, “dementia” and “psychiatric disorder” to collect published controlled studies on this topic.</p></div><div><h3>Results</h3><p>Eighteen reports were identified, which investigated the association between blood types and various psychiatric disorders. Some studies reported that the AB blood type was correlated with higher levels of anxiety and cognitive impairment. Another study found that individuals with bipolar or unipolar affective disorder had a higher prevalence of type O blood and a significantly lower rate of type A blood. However, patients with involutional depression were reported to have a higher rate of type A blood and significantly lower rate of type O. None of the blood types were found to have any significant association with risk for dementia, nor were there any significant differences in blood type between those with schizophrenia and healthy controls. Several studies also reported negative findings between blood type and the occurrence of different affective disorders.</p></div><div><h3>Discussion</h3><p>The studies in this review suggest a possible connection between ABO blood types and certain psychiatric disorders, as well as highlight the controversy in this field of research. How blood types predispose to some mental disorders has not been fully explored and warrants further investigation.</p></div>","PeriodicalId":52767,"journal":{"name":"Biomarkers in Neuropsychiatry","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50187492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biomarkers in multiple sclerosis: An update 多发性硬化症的生物标志物：最新进展

Biomarkers in Neuropsychiatry Pub Date : 2023-09-12 DOI: 10.1016/j.bionps.2023.100075

Jad Costa , Gabrielle Macaron , Karine J. Abou Khaled

引用次数: 0

Biomarkers in Parkinson’s disease: A state of the art review 帕金森病的生物标志物：最新进展

Biomarkers in Neuropsychiatry Pub Date : 2023-09-09 DOI: 10.1016/j.bionps.2023.100074

Kyla Y. Yamashita , Sweta Bhoopatiraju , Bret D. Silverglate , George T. Grossberg

引用次数: 0

Basal ganglia atrophy as a marker of multiple sclerosis progression 基底神经节萎缩是多发性硬化症进展的标志

Biomarkers in Neuropsychiatry Pub Date : 2023-09-07 DOI: 10.1016/j.bionps.2023.100073

Artem Trufanov , Alexander Krasichkov , Alexey Polushin , Dmitry Skulyabin , Aleksandr Efimtsev , Igor Litvinenko , Evgeniya Kuznetsova , Dmitrii Medvedev , Gennady Bisaga

{"title":"Basal ganglia atrophy as a marker of multiple sclerosis progression","authors":"Artem Trufanov , Alexander Krasichkov , Alexey Polushin , Dmitry Skulyabin , Aleksandr Efimtsev , Igor Litvinenko , Evgeniya Kuznetsova , Dmitrii Medvedev , Gennady Bisaga","doi":"10.1016/j.bionps.2023.100073","DOIUrl":"10.1016/j.bionps.2023.100073","url":null,"abstract":"<div><p>This study presents the findings of the magnetic resonance morphometric analysis of brain subcortical structures in patients with remitting relapsing multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS) phenotypes in comparison with the control group. The study revealed significant differences between the volume of the left nucleus accumbens [control:RRMS= 570,108 ± 100,024:487,851 ± 124,174; F(p) ANOVA= <0001] and the volume of the left globus pallidus [control:RRMS= 2076,247 ± 290,695: 1855,851 ± 280,476; F(p) ANOVA= <0001] in patients with the relapsing remitting phenotype. Patients with the secondary progressive phenotype showed a statistically valid decrease in volume for multiple subcortical structures: the left caudate nucleus [control:SPMS= 3686,500 ± 501,966:3108,946 ± 565,138; F(p) ANOVA= 0.001], right caudate nucleus [control:SPMS= 3772,550 ± 508,087:3242,292 ± 650,215; F(p) ANOVA= 0003], left putamen [control:SPMS= 5130,781 ± 547,844: 4164,967 ± 1076,993; F(p) ANOVA= <0001], right putamen [control:SPMS= 5096,303 ± 611,397: 4281,046 ± 1100,752; F(p) ANOVA= 0001], left globus pallidus [control:SPMS= 2076,247 ± 290.696:1800,913 ± 296,609; F(p) ANOVA= <0001], left nucleus accumbens [control:SPMS= 570,108 ± 100,024;458,904 ± 131,690; F(p) ANOVA= 0001], right nucleus accumbens [control:SPMS= 587,567 ± 100,542: 447,375 ± 103,687; F(p) ANOVA= <0001]. The increase in EDSS was significantly correlated with the decrease in right nucleus accumbens in both RRMS and SPMS. The investigation revealed potential subcortex structures (nucleus accumbens) that could be considered as markers for the transition of RRMS to SPMS.</p></div>","PeriodicalId":52767,"journal":{"name":"Biomarkers in Neuropsychiatry","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42634892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neural correlates of severity in major depressive disorder: A combined structural and resting-state functional MRI study 重度抑郁症严重程度的神经相关性:一项结构和静息状态功能MRI联合研究

Biomarkers in Neuropsychiatry Pub Date : 2023-09-01 DOI: 10.1016/j.bionps.2023.100072

Xiaoliu Zhang , Jun Cao , Xiaorong Chen , Qian Huang , Su Hong , Jianmei Chen , Ming Ai , Yao Gan , Jinglan He , Li Kuang

{"title":"Neural correlates of severity in major depressive disorder: A combined structural and resting-state functional MRI study","authors":"Xiaoliu Zhang , Jun Cao , Xiaorong Chen , Qian Huang , Su Hong , Jianmei Chen , Ming Ai , Yao Gan , Jinglan He , Li Kuang","doi":"10.1016/j.bionps.2023.100072","DOIUrl":"10.1016/j.bionps.2023.100072","url":null,"abstract":"<div><p>Major depressive disorder (MDD) is a disabling and severe psychiatric disorder with high risk of suicide, and adulthood is one of the most probable period for the onset. The neural basis underlying the young adults with MDD remains underexplored. In this study, we have investigated the cortical and subcortical alterations of neuroanatomical structures and functional activation in twenty-three young depressive patients with suicide attempt versus forty-five healthy controls. Significant disruptions of regional gray matter volume at left middle frontal extending to superior frontal involved with cognitive processing were found correlated with anxiety scores in MDD patients. Increased cortical thickness at right orbital frontal responsible for decision making was correlated with severity of suicide. Further, increased functional activation at left auditory association cortex was a hallmark of hallucinations in MDD, which was directly associated with depression severity. Moreover, decreased spontaneous brain activity at right inferior frontal was also found, reflecting lower inhibition control in MDD patients. The abnormal structural and functional findings at fronto-cortical areas implied the dysfunctional cognitive control and emotion regulation in MDD. The alterations correlated with clinical scores might indicate the reliable neural markers for MDD.</p></div>","PeriodicalId":52767,"journal":{"name":"Biomarkers in Neuropsychiatry","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43421341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cerebrospinal fluid biomarkers for normal pressure hydrocephalus 正常压力脑积水的脑脊液生物标志物

Biomarkers in Neuropsychiatry Pub Date : 2023-08-11 DOI: 10.1016/j.bionps.2023.100071

Derya Kaya, Ahmet Turan Isik

{"title":"Cerebrospinal fluid biomarkers for normal pressure hydrocephalus","authors":"Derya Kaya, Ahmet Turan Isik","doi":"10.1016/j.bionps.2023.100071","DOIUrl":"https://doi.org/10.1016/j.bionps.2023.100071","url":null,"abstract":"<div><p>Idiopathic normal pressure hydrocephalus (iNPH) is a potentially reversible disease characterized by gait disturbance, a frontal-subcortical pattern of cognitive impairment, and urinary incontinence with disproportionately enlarged ventricles. Its prevalence rises with aging. Patients with iNPH are treated with shunt placement, and predicting the surgical outcome is not always easy. Cerebrospinal fluid (CSF) has inevitably been an attractive matrix for biomarker identification in both the diagnosis and treatment of iNPH and the disease may have individual CSF composition changes. Additionally, in order to detect iNPH earlier, implement treatment faster, and have better therapeutic effects, the incorporation of CSF biomarkers in the diagnostic and treatment process is essential. In this review, CSF biomarkers of Alzheimer’s disease pathology, axonal damage, neuronal damage, astroglial dysfunction, myelin damage, inflammation, and extracellular matrix protein remodeling have been evaluated and tried to emphasize those of which have highly consistent findings in the studies. CSF samples collected only at a single time point may not be sufficient to identify a promising marker in such a dynamic and used to be a common comorbid condition to other neurodegenerative diseases. These confounders demonstrate the limitations of using solely biomarkers to diagnose the disease and to foresee the outcome of the shunt surgery. Therefore, CSF samples collected antemortem at different time points and biopsy-confirmed iNPH patients with and without other neurodegenerative diseases would fill the gaps in identifying a valid biomarker. Longitudinal observations of shunt responders and non-responders in multicenter with well-defined cohorts are also needed to understand iNPH-specific markers. Finally, biomarkers of a bioinformatic approach that includes micro-RNAs, extracellular vesicles, metabolomics, the microbiome, or else are warranted to identify novel and useful diagnostic and prognostic biomarker tools in iNPH.</p></div>","PeriodicalId":52767,"journal":{"name":"Biomarkers in Neuropsychiatry","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50187064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reliability of resting-state electrophysiology in fragile X syndrome 脆性X综合征静息状态电生理的可靠性

Biomarkers in Neuropsychiatry Pub Date : 2023-07-19 DOI: 10.1016/j.bionps.2023.100070

Rui Liu , Ernest V. Pedapati , Lauren M. Schmitt , Rebecca C. Shaffer , Elizabeth G. Smith , Kelli C. Dominick , Lisa A. DeStefano , Grace Westerkamp , Paul Horn , John A. Sweeney , Craig A. Erickson

{"title":"Reliability of resting-state electrophysiology in fragile X syndrome","authors":"Rui Liu , Ernest V. Pedapati , Lauren M. Schmitt , Rebecca C. Shaffer , Elizabeth G. Smith , Kelli C. Dominick , Lisa A. DeStefano , Grace Westerkamp , Paul Horn , John A. Sweeney , Craig A. Erickson","doi":"10.1016/j.bionps.2023.100070","DOIUrl":"10.1016/j.bionps.2023.100070","url":null,"abstract":"<div><h3>Objective</h3><p>Fragile X Syndrome (FXS) is the leading monogenic cause of intellectual disability and autism spectrum disorder. Currently, there are no established biomarkers for predicting and monitoring drug effects in FXS, and no approved therapies are available. Previous studies have shown electrophysiological changes in the brain using electroencephalography (EEG) in individuals with FXS and animal models. These changes may be influenced by drug therapies. In this study, we aimed to assess the reliability of resting-state EEG measures in individuals with FXS, which could potentially serve as a biomarker for drug discovery.</p></div><div><h3>Methods</h3><p>We collected resting-state EEG data from 35 individuals with FXS participating in placebo-controlled clinical trials (23 males, 12 females; visit age mean+/-std 25.6 +/−8.3). The data were analyzed for various spectral features using intraclass correlation analysis to evaluate test-retest reliability. The intervals between EEG recordings ranged from same-day measurements to up to six weeks apart.</p></div><div><h3>Results</h3><p>Our results showed high reliability for most spectral features, with same-day reliability exceeding 0.8. Features of interest demonstrated ICC values of 0.60 or above at longer intervals. Among the features, alpha band relative power exhibited the highest reliability.</p></div><div><h3>Conclusion</h3><p>These findings indicate that resting-state EEG can provide consistent and reproducible measures of brain activity in individuals with FXS. This supports the potential use of EEG as an objective biomarker for evaluating the effects of new drugs in FXS.</p></div><div><h3>Significance</h3><p>The reliable measurements obtained from power spectrum-based resting-state EEG make it a promising tool for assessing the impact of small molecule drugs in FXS.</p></div>","PeriodicalId":52767,"journal":{"name":"Biomarkers in Neuropsychiatry","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43207735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can neurocognitive assessment be a lower-cost substitute for biomarkers in predicting progression from mild cognitive impairment (MCI) to Alzheimer’s disease (AD)? A narrative review 在预测从轻度认知障碍（MCI）到阿尔茨海默病（AD）的进展方面，神经认知评估能否成为生物标志物的低成本替代品？叙述性评论

Biomarkers in Neuropsychiatry Pub Date : 2023-07-11 DOI: 10.1016/j.bionps.2023.100069

Lea Daou , Alaeddine El Alayli , Fadi Constantinos , Georgette Dib , Marc Barakat

引用次数: 0